TY - JOUR
T1 - Impact of treatment year on survival and adverse effects in patients with cervical cancer and paraortic lymph node metastases treated with definitive extended-field radiation therapy
AU - Osborne, Eleanor M.
AU - Klopp, Ann H.
AU - Jhingran, Anuja
AU - Meyer, Larissa A.
AU - Eifel, Patricia J.
N1 - Publisher Copyright:
© 2016 American Society for Radiation Oncology
PY - 2017/5
Y1 - 2017/5
N2 - Purpose Treatment for locoregionally advanced cervical cancer has changed dramatically since 2000. In that year, delivery of radiation therapy with concurrent chemotherapy became standard, and in the early 2000s, use of intensity modulated RT (IMRT) and positron emission tomography (PET) became more prevalent. We sought to determine the impact of these changes on disease-specific survival (DSS) and treatment-related adverse effects in patients with cervical cancer with para-aortic lymph node (PAN) metastases treated with definitive extended-field radiation therapy. Methods and materials We reviewed the medical records of 103 patients with cervical cancer with PAN metastases treated with curative intent at our institution during 2000 to 2013. DSS, disease control in PANs, and treatment-associated adverse effects were compared between patient groups defined by treatment year. Results The 5-year DSS rate was 23% (95% confidence interval, 9%-38%) for the 34 patients treated from 2000 to 2004, and 47% (95% confidence interval, 36%-59%) for the 69 patients treated from 2005 to 2013 (P =.005). Factors associated with improved DSS included concurrent chemoradiation (P =.001), baseline PET imaging (P =.01), and treatment of PANs with IMRT (P =.02). Only 3 patients (4%) treated from 2005 to 2013 versus 6 patients (18%) treated from 2000 to 2004 had recurrence in PANs (P =.03). Most recurrences in patients treated from 2005 to 2013 were at distant sites. The crude rate of grade 3 or higher late treatment-related adverse effects was 17%; of the 18 patients who developed serious adverse effects, 8 were being treated for recurrent disease at the time. Adverse effects most frequently involved the gastrointestinal and genitourinary systems. Conclusions Outcomes for patients with cervical cancer with PAN metastases have improved concurrently with advances in treatment, including PET and IMRT. Future studies should focus on ways to improve systemic treatments and reduce late adverse effects without compromising local control.
AB - Purpose Treatment for locoregionally advanced cervical cancer has changed dramatically since 2000. In that year, delivery of radiation therapy with concurrent chemotherapy became standard, and in the early 2000s, use of intensity modulated RT (IMRT) and positron emission tomography (PET) became more prevalent. We sought to determine the impact of these changes on disease-specific survival (DSS) and treatment-related adverse effects in patients with cervical cancer with para-aortic lymph node (PAN) metastases treated with definitive extended-field radiation therapy. Methods and materials We reviewed the medical records of 103 patients with cervical cancer with PAN metastases treated with curative intent at our institution during 2000 to 2013. DSS, disease control in PANs, and treatment-associated adverse effects were compared between patient groups defined by treatment year. Results The 5-year DSS rate was 23% (95% confidence interval, 9%-38%) for the 34 patients treated from 2000 to 2004, and 47% (95% confidence interval, 36%-59%) for the 69 patients treated from 2005 to 2013 (P =.005). Factors associated with improved DSS included concurrent chemoradiation (P =.001), baseline PET imaging (P =.01), and treatment of PANs with IMRT (P =.02). Only 3 patients (4%) treated from 2005 to 2013 versus 6 patients (18%) treated from 2000 to 2004 had recurrence in PANs (P =.03). Most recurrences in patients treated from 2005 to 2013 were at distant sites. The crude rate of grade 3 or higher late treatment-related adverse effects was 17%; of the 18 patients who developed serious adverse effects, 8 were being treated for recurrent disease at the time. Adverse effects most frequently involved the gastrointestinal and genitourinary systems. Conclusions Outcomes for patients with cervical cancer with PAN metastases have improved concurrently with advances in treatment, including PET and IMRT. Future studies should focus on ways to improve systemic treatments and reduce late adverse effects without compromising local control.
UR - http://www.scopus.com/inward/record.url?scp=85001754560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85001754560&partnerID=8YFLogxK
U2 - 10.1016/j.prro.2016.09.003
DO - 10.1016/j.prro.2016.09.003
M3 - Article
C2 - 27743802
AN - SCOPUS:85001754560
SN - 1879-8500
VL - 7
SP - e165-e173
JO - Practical radiation oncology
JF - Practical radiation oncology
IS - 3
ER -